Socio-economic Status is an Independent Predictor of Long-term Survival and Readmissions in Heart Failure

2010 ◽  
Vol 19 ◽  
pp. S80
Author(s):  
J. Finn ◽  
T. Teng ◽  
M. Knuiman ◽  
M. Hobbs ◽  
J. Hung ◽  
...  
Keyword(s):  
Heart Failure ◽  
Independent Predictor ◽  
Economic Status ◽  
Term Survival ◽  
Long Term Survival ◽  
Socio Economic Status

A California population-based study on long-term survivors of hepatocellular carcinoma.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 195-195
Author(s):  
Somasundaram Subramaniam ◽  
Juan Yang ◽  
Daphne Lichtensztajn ◽  
Christina A Clarke
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Characteristics ◽  
Clinical Laboratory ◽  
Economic Status ◽  
The United States ◽  
Term Survival ◽  
Long Term Survival ◽  
Socio Economic Status ◽  
Long Term Survivors

195 Background: Hepatocellular carcinoma (HCC) is becoming increasingly common in the United States and long-term survival remains dismal, with only 15% of patients surviving more than 5 years. Little is known about the demographic and clinical characteristics of patients who survive. Methods: Using data from the California Cancer Registry, a member of the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) program, we identified all patients diagnosed with hepatocellular carcinoma between 1988 and 2007. Patients were included if they had pathological, clinical, laboratory or radiological confirmation of diagnosis. Patient’s demographic information including socio-economic status, summary stage, tumor characteristics and treatment details were included in the analysis. Hazard ratios (HR) for survival were calculated using Cox proportional hazards regression modeling. Results: We identified 19,855 patients with a median age of diagnosis of 63. Patients were predominantly male (74.4%). The majority of patients were Non-Hispanic Whites (38.1%) followed by Asian and Pacific Islander (API) (30.4%) and Hispanics (23.2%). Of the entire cohort, 3546 (17.9%) survived at least 3 years. Amongst long-term survivors, when classified by summary stage, 2552 (72%) were localized, 556 (15.7%) regional, 217 (6.1%) remote and 221 (6.2%) unknown. In a multivariate model, variables associated with survival were resection or transplant (HR 0.31), liver-directed therapies (0.53), chemotherapy (0.64), academic status of treating hospital (0.74), API race (0.832), highest socio-economic status quintile (0.88), female gender (0.93) and Hispanic race (0.94). When stratified by summary stage, API race, receipt of surgery, receipt of liver-directed therapies and treatment in an academic hospital remained significantly associated with long-term survival across all stages. Conclusions: Patients who survive for 3 years after a diagnosis of HCC have distinct demographic and clinical characteristics from patients who do not survive.

Short-term weight loss after hospitalization predicts long-term survival in patients with chronic heart failure

2006 ◽  
Vol 31 (03) ◽  
Author(s):  
M Lainscak ◽  
S von Haehling ◽  
A Sandek ◽  
I Keber ◽  
M Kerbev ◽  
...  
Keyword(s):  
Heart Failure ◽  
Weight Loss ◽  
Chronic Heart Failure ◽  
Short Term ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure

Heart ◽  
2021 ◽  
Vol 107 (5) ◽  
pp. 389-395
Author(s):  
Jianhua Wu ◽  
Alistair S Hall ◽  
Chris P Gale
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Life Expectancy ◽  
Survival Benefit ◽  
Ace Inhibition ◽  
Survival Times ◽  
Term Survival ◽  
Long Term Survival

AimsACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population.MethodsIn 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0–29.6 years).ResultsBy 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%.ConclusionFor patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.

scholarly journals Ventricular conduction abnormalities as predictors of long‐term survival in acute de novo and decompensated chronic heart failure

2015 ◽  
Vol 3 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Heli Tolppanen ◽  
Krista Siirila‐Waris ◽  
Veli‐Pekka Harjola ◽  
David Marono ◽  
Jiri Parenica ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
De Novo ◽  
Term Survival ◽  
Long Term Survival ◽  
Conduction Abnormalities ◽  
Ventricular Conduction

scholarly journals Left atrial function index predicts long-term survival in stable outpatients with systolic heart failure

2016 ◽  
Vol 18 (2) ◽  
pp. 119-127 ◽  
Author(s):  
Luis Sargento ◽  
Andre Vicente Simões ◽  
Susana Longo ◽  
Nuno Lousada ◽  
Roberto Palma dos Reis
Keyword(s):  
Heart Failure ◽  
Left Atrial ◽  
Systolic Heart Failure ◽  
Atrial Function ◽  
Left Atrial Function ◽  
Term Survival ◽  
Long Term Survival ◽  
Function Index

scholarly journals Long-term outcomes in patients with critical limb ischemia and heart failure with preserved or reduced ejection fraction

2017 ◽  
Vol 22 (4) ◽  
pp. 307-315 ◽  
Author(s):  
Kavita B Khaira ◽  
Ellen Brinza ◽  
Gagan D Singh ◽  
Ezra A Amsterdam ◽  
Stephen W Waldo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Left Ventricular ◽  
Term Survival ◽  
Long Term Survival ◽  
Reduced Ejection Fraction ◽  
History Of

The impact of heart failure (HF) on long-term survival in patients with critical limb ischemia (CLI) has not been well described. Outcomes stratified by left ventricular ejection fraction (EF) are also unknown. A single center retrospective chart review was performed for patients who underwent treatment for CLI from 2006 to 2013. Baseline demographics, procedural data and outcomes were analyzed. HF diagnosis was based on appropriate signs and symptoms as well as results of non-invasive testing. Among 381 CLI patients, 120 (31%) had a history of HF and 261 (69%) had no history of heart failure (no-HF). Within the HF group, 74 (62%) had HF with preserved ejection fraction (HFpEF) and 46 (38%) had HF with reduced ejection fraction (HFrEF). The average EF for those with no-HF, HFpEF and HFrEF were 59±13% vs 56±9% vs 30±9%, respectively. The likelihood of having concomitant coronary artery disease (CAD) was lowest in the no-HF group (43%), higher in the HFpEF group (70%) and highest in the HFrEF group (83%) ( p=0.001). Five-year survival was on average twofold higher in the no-HF group (43%) compared to both the HFpEF (19%, p=0.001) and HFrEF groups (24%, p=0.001). Long-term survival rates did not differ between the two HF groups ( p=0.50). There was no difference in 5-year freedom from major amputation or freedom from major adverse limb events between the no-HF, HFpEF and HFrEF groups, respectively. Overall, the combination of CLI and HF is associated with poor 5-year survival, independent of the degree of left ventricular systolic dysfunction.

Sign in / Sign up

Export Citation Format

Share Document